Prevention of COVID-19-induced hyperinflammatory syndrome with the immunomodulatory protein AIP-2”

Therapeutic Innovation Australia 2026 Open access

Read full text
Authors: Therapeutic Innovation Australia
DOI: 10.82292/f7fc-cm44
Cited by: 0

Fields of Study & Subjects

COVID-19 Clinical Research Studies Kawasaki Disease and Coronary Complications Inflammasome and immune disorders

Publication details

Journal / source
Therapeutic Innovation Australia
Publication date
16 February 2026
Language
EN